MedPath

Amikacin Sulfate

Amikacin Sulfate Injection, USP

Approved
Approval ID

c0f57839-1c9b-49e5-8c7a-708e2d16495d

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 31, 2023

Manufacturers
FDA

Fresenius Kabi USA, LLC

DUNS: 608775388

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Amikacin Sulfate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code63323-815
Application NumberANDA205604
Product Classification
M
Marketing Category
C73584
G
Generic Name
Amikacin Sulfate
Product Specifications
Route of AdministrationINTRAVENOUS, INTRAMUSCULAR
Effective DateMay 31, 2023
FDA Product Classification

INGREDIENTS (5)

SODIUM METABISULFITEInactive
Code: 4VON5FNS3C
Classification: IACT
AMIKACIN SULFATEActive
Quantity: 250 mg in 1 mL
Code: N6M33094FD
Classification: ACTIM
TRISODIUM CITRATE DIHYDRATEInactive
Code: B22547B95K
Classification: IACT
SULFURIC ACIDInactive
Code: O40UQP6WCF
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Amikacin Sulfate - FDA Drug Approval Details